Related Experiment Video
Updated: Jun 10, 2026
07:42
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Update on antifungal agents for paediatric patients
1Centre for Bone Marrow Transplantation and Department of Paediatric Haematology/Oncology, University Children's Hospital, Muenster, Germany. grollan@ukmuenster.de
Summary
New antifungal drugs offer hope for children with invasive fungal infections. Understanding their use in pediatric patients is crucial for effective treatment and improved outcomes.
Area of Science:
- Pediatric Infectious Diseases
- Mycology
- Pharmacology
Background:
- Fungal infections present unique challenges in pediatric populations due to differences in biology and predisposing conditions.
- Invasive fungal infections remain a significant cause of illness and death in immunocompromised children.
- Recent advancements have introduced new antifungal agents, necessitating updated clinical guidance.
Purpose of the Study:
- To provide an updated review of antifungal agents for pediatric use.
- To detail the pharmacokinetics, safety, dosing, and clinical indications of these agents in children.
- To support clinicians in managing complex antifungal therapy in pediatric patients.
Main Methods:
- Review of recent literature on antifungal agents in pediatric populations.
- Analysis of pharmacokinetic and safety data for new and existing antifungal drugs.
- Compilation of current clinical guidelines and evidence for pediatric antifungal use.
Main Results:
- Several new antifungal agents have been developed, with significant progress in pediatric drug development.
- Antifungal therapy in children is becoming more complex, requiring specialized knowledge.
- Updated information on pharmacokinetics, safety, dosing, and indications is essential for effective treatment.
Conclusions:
- New antifungal agents represent a significant therapeutic advance for pediatric invasive fungal infections.
- Comprehensive understanding of antifungal pharmacokinetics, safety, and dosing is critical for successful pediatric patient management.
- Continued research and development are needed to optimize antifungal strategies in immunocompromised children.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...